Cirrhosis Treatments

Find Cirrhosis Treatments

Generic Name

Ursodiol

Brand Names

Reltone, Urso, Urso 250, Ursolign

FDA approval date: December 31, 1987

Classification: Bile Acid

Form: Tablet, Capsule

What is Reltone (Ursodiol)?

1. Reltone™ is indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. Safety of use of Reltone™ beyond 24 months is not established. 2. Reltone™ is indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Multi-center, Randomized, Double-blind, Active Controlled, Parallel Clinical Trial for the Evaluation of the Efficacy and Safety of CnU Cap. 750 mg in Patients With Cholesterol Gallstone

Enrollment Status: Recruiting

Publish Date: July 29, 2026

Intervention Type: Drug

Study Phase: Phase 4

Summary: The objective of this clinical trial is to evaluate the efficacy and safety of CnU capsule 750 mg administration in patients with Cholesterol gallstone (radiolucent gallstones)

Study on Immunotherapy Enhancement Strategies for Muscle-invasive Bladder Cancer

Enrollment Status: Recruiting

Publish Date: July 21, 2026

Intervention Type: Drug, Procedure

Study Phase: Phase 2

Summary: This is a multicenter, prospective, open-label, Phase II, four-arm parallel study evaluating the efficacy and safety of different sensitization strategies combined with disitamab vedotin and toripalimab in patients with HER2-positive muscle-invasive urothelial carcinoma of the bladder (MIBC). Eligible patients with cT2-4aN0M0 HER2-positive urothelial carcinoma of the bladder will receive neoadjuva...

A Randomized, Double-Blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of CS0159 in Patients With Primary Biliary Cholangitis (PBC) With Inadequate Response or Intolerance to Ursodeoxycholic Acid (UDCA)

Enrollment Status: Recruiting

Publish Date: July 08, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: A Randomized, Double-Blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of CS0159 in Patients with Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (UDCA).

View All Clinical Trials